Never underestimate the love people have for their
Post# of 148288
Hopefully, Dr Wood learned a lot about CCR5 receptor role, in immunology, from his work with Maraviroc. If he cared about his project, then he should have been following Leronlimab. Maybe, Maraviroc wasn't the main goal of his project. Maybe his main goal was to develop a successful CCR5 antagonist program, and his drug just didn't quite live up to his expectations. Now, he is with GSK! He has a responsibility to help them succeed. Maybe, he thinks he is getting another chance to set the world on fire. Who knows what is going through his mind. One thing should be certain, he knows the limitations of Maraviroc. He should be aware that the science has not limited Leronlimab. Bad business has been the only limitation (maybe some sabotage as well). If you look at it that way, maybe he sees opportunity!
Read More: https://investorshangout.com/post/view?id=644...z7Zbv613tQ